Metagenomic analysis reveals effects of gut microbiome in response to neoadjuvant chemoradiotherapy in advanced rectal cancer

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2024-10-15 DOI:10.1016/j.ygeno.2024.110951

Hao Chen , Meizi Zeng , Syeda Sundas Batool , Yiming Zhao , Zheng Yu , Jumei Zhou , Ke Liu , Jing Huang

{"title":"Metagenomic analysis reveals effects of gut microbiome in response to neoadjuvant chemoradiotherapy in advanced rectal cancer","authors":"Hao Chen , Meizi Zeng , Syeda Sundas Batool , Yiming Zhao , Zheng Yu , Jumei Zhou , Ke Liu , Jing Huang","doi":"10.1016/j.ygeno.2024.110951","DOIUrl":null,"url":null,"abstract":"<div><div>Neoadjuvant chemoradiotherapy can enhance survival rate of patients with advanced rectal cancer, but its effectiveness varies considerably. Previous studies have indicated that gut microbes may serve as biomarkers for predicting treatment efficacy. However, the specific roles of the gut microbiome in patients who have good response to nCRT remains unclear. In this study, shotgun metagenomic sequencing technology was used to analyze the fecal microbiome of patients with varying responses to nCRT. Our findings revealed that beneficial intestinal bacteria and genes from different metabolic pathways (carbohydrate metabolism, amino acid metabolism, and sulfur metabolism) were significantly enriched in patients with good response. Additionally, causal relationship in which microbial-derived GDP-D-rhamnose and butyrate could influence the response to nCRT was clarified. Our results offered new insights into the different response to nCRT, and provided valuable reference points for improving the effectiveness of nCRT in patients with advanced colorectal cancer.</div></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0888754324001721","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

Neoadjuvant chemoradiotherapy can enhance survival rate of patients with advanced rectal cancer, but its effectiveness varies considerably. Previous studies have indicated that gut microbes may serve as biomarkers for predicting treatment efficacy. However, the specific roles of the gut microbiome in patients who have good response to nCRT remains unclear. In this study, shotgun metagenomic sequencing technology was used to analyze the fecal microbiome of patients with varying responses to nCRT. Our findings revealed that beneficial intestinal bacteria and genes from different metabolic pathways (carbohydrate metabolism, amino acid metabolism, and sulfur metabolism) were significantly enriched in patients with good response. Additionally, causal relationship in which microbial-derived GDP-D-rhamnose and butyrate could influence the response to nCRT was clarified. Our results offered new insights into the different response to nCRT, and provided valuable reference points for improving the effectiveness of nCRT in patients with advanced colorectal cancer.

查看原文本刊更多论文

元基因组分析揭示了肠道微生物组对晚期直肠癌新辅助放化疗反应的影响。

新辅助化放疗可提高晚期直肠癌患者的生存率，但其疗效差异很大。以往的研究表明，肠道微生物可作为预测治疗效果的生物标志物。然而，肠道微生物组在对 nCRT 反应良好的患者中的具体作用仍不清楚。本研究采用枪式元基因组测序技术分析了对nCRT有不同反应的患者的粪便微生物组。我们的研究结果表明，有益肠道细菌和不同代谢途径（碳水化合物代谢、氨基酸代谢和硫代谢）的基因在反应良好的患者中明显富集。此外，我们还阐明了微生物衍生的 GDP-D 鼠李糖和丁酸盐影响 nCRT 反应的因果关系。我们的研究结果为了解晚期结直肠癌患者对 nCRT 的不同反应提供了新的见解，并为提高晚期结直肠癌患者 nCRT 的疗效提供了有价值的参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567